IP Library Granted Patent US 11,034,717
Granted Patent B2
US 11,034,717 · App. 15/288,390 · Granted Jun 15, 2021

Farnesoid X receptor modulators

Inventors: Roberto Pellicciari (Perugia, IT); Antimo Gioiello (Perugia, IT)
Assignee: Intercept Pharmaceuticals, Inc.
C07J43/003C07J9/00C07J9/005C07J31/006C07J41/0083C07J41/0055C07J41/0061C07J41/0094C07J71/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,034,717
App. No.
15/288,390
Granted
Jun 15, 2021
Kind
B2
Abstract

The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R 1 -R 10 , m, n, p, and are as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.

Claims (15)

1. A compound selected from:

or a pharmaceutically acceptable salt or solvate thereof.

2. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient.

3. The compound of claim 1 , which is

or a pharmaceutically acceptable salt or solvate thereof.

4. The compound of claim 3 , which is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 3 , which is

6. The compound of claim 1 , which is

or a pharmaceutically acceptable salt or solvate thereof.

7. The compound of claim 6 , which is

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 6 , which is

9. A pharmaceutical composition comprising the compound of claim 3 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient.

10. A pharmaceutical composition comprising the compound of claim 6 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2026
From: INTERCEPT PHARMACEUTICALS, INC.
To: ALFASIGMA S.P.A
Reel/Frame 075044/0679 →
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0990 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2021
From: PELLICCIARI, ROBERTO; GIOIELLO, ANTIMO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 056111/0417 →
Continuity (2)
Provisional Application 62238246 · Oct 7, 2015
Related Publication 20170101434A1 · Apr 13, 2017
Cited By (1)
US 12,291,549